Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging

Breast Journal

Volumn 18, Issue 6, 2012, Pages 527-534

  King, Valencia ^a   Kaplan, Jennifer ^a   Pike, Malcolm C ^a   Liberman, Laura ^a   David Dershaw, D ^a   Lee, Carol H ^a   Brooks, Jennifer D ^a   Morris, Elizabeth A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

breast; enhancement; magnetic resonance imaging; tamoxifen

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST; BREAST CANCER; BREAST CYST; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CONTROLLED STUDY; FEMALE; FIBROGLANDULAR TISSUE; HUMAN; HUMAN TISSUE; IMAGE ENHANCEMENT; IRRADIATION; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST CYST; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868569550     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12002     Document Type: Article

References (23)

1. Oksa S, Parkkola R, Luukkaala T, Maenpaa J,. Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. Acta Radiol 2009; 50: 984-9.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-88. (Pubitemid 28439961)
3. Rutqvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991; 83: 1299-306.
4. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS,. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991; 83: 1450-9.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
6. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
7. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997; 203: 137-44. (Pubitemid 27142721)
8. Muller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, Claussen CD,. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997; 203: 145-9. (Pubitemid 27142722)
9. Hussain Z, Roberts N, Whitehouse GH, Garcia-Finana M, Percy D,. Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. Br J Radiol 1999; 72: 236-45. (Pubitemid 29154669)
10. Graham SJ, Stanchev PL, Lloyd-Smith JO, Bronskill MJ, Plewes DB,. Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 T. J Magn Reson Imaging 1995; 5: 695-701.
11. Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Halpern EF, Garrido L,. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging-initial observations. Radiology 2005; 235: 36-41. (Pubitemid 40432232)
12. Harvey JA, Santen RJ, Petroni GR, et al. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Menopause 2008; 15: 67-73.
13. Pfleiderer SO, Sachse S, Sauner D, et al. Changes in magnetic resonance mammography due to hormone replacement therapy. Breast Cancer Res 2004; 6: R232-8.
14. Morris EA,. Diagnostic breast MR imaging: current status and future directions. Radiol Clin North Am 2007; 45: 863-80, vii. (Pubitemid 47410063)
15. Kuhl C,. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology 2007; 244: 356-78. (Pubitemid 47080868)
16. Son HJ, Oh KK,. Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 1999; 173: 905-9.
17. Mousa NA, Crystal P, Wolfman WL, Bedaiwy MA, Casper RF,. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy. Menopause 2008; 15: 875-84.
18. American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS), 2nd edn. Reston, VA: American College of Radiology, 2003.
19. Eng-Wong J, Orzano-Birgani J, Chow CK, et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 1696-701.
20. Cuzick J, Warwick J, Pinney E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011; 103: 744-52.
21. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA,. Background Parenchymal Enhancement at Breast MR Imaging and Breast Cancer Risk. Radiology 2011; 260: 50-60.
22. American College of Radiology BI-RADS Committee. Breast Imaging Reporting and Data System, 4th edn. Reston, VA: American College of Radiology (ACR), 2003.
23. Finlayson CA, Lewin JM, Rabinovitch R, et al. MRI is a potential intermediate marker for tamoxifen response in breast cancer prevention. Breast Cancer Res Tr 2003; 82: S178-S78.